An ANA antinuclear antibody profile is a blood test that detects antibodies targeting cell nucleus components. It helps screen for and support diagnosis of autoimmune connective-tissue diseases such as systemic lupus erythematosus, scleroderma, Sjögren’s syndrome and some forms of inflammatory arthritis. Results report titer and staining pattern; positive results prompt further specific antibody testing and clinical correlation, since low-level positives can occur in healthy people.

ANA is usually reported as a titre by indirect immunofluorescence: results below 1:40 are generally considered negative, though some labs use 1:80 as the cutoff, so low titres (1:40–1:80) may be clinically insignificant. ELISA/solid‑phase tests give index values with lab-specific reference ranges. Always use the lab’s reference interval and correlate ANA results with clinical findings.

An ANA profile shows whether antinuclear antibodies are present, the titer and the immunofluorescence pattern. Negative results make systemic autoimmune disease less likely; low titers can be nonspecific, while higher titers (e.g., ≥1:160) are more suggestive of autoimmune conditions. Pattern clues—homogeneous (SLE), speckled (Sjögren’s, SLE), centromere (CREST), nucleolar (scleroderma). Always correlate with symptoms and follow up with specific antibody tests and clinical assessment.

An ANA (antinuclear antibody) blood test in pregnancy screens for autoimmune antibodies that may indicate conditions like systemic lupus. A positive result is nonspecific but prompts further testing for specific antibodies (e.g., anti‑Ro/La) and closer obstetric and rheumatology monitoring, since autoimmune disease can raise risks of miscarriage, preeclampsia, fetal growth issues, or neonatal lupus. Management is individualized.

An ANA (antinuclear antibody) test screens for autoimmune disorders such as lupus, rheumatoid arthritis and scleroderma. A positive result isn’t automatically serious — low titers can appear in healthy people, infections, or medication use. Interpretation depends on titer, pattern and symptoms; high titers or compatible symptoms warrant specialist evaluation and further testing. Discuss results and next steps with your doctor.

ANA profile testing costs vary by country and method. In India it typically ranges from about ₹600–₹3,000; in the United States from roughly $50–$400 depending on assay type and insurance; in the UK the test is usually covered by the NHS, while private labs charge about £30–£150. Additional reflex testing or extended antibody panels can increase the price.